









The Centre for Health Economics Research and Evaluation (CHERE) was 
established in 1991.  CHERE is a centre of excellence in health economics and 
health services research. It is a joint Centre of the Faculties of Business 
and Nursing, Midwifery and Health at the University of Technology, Sydney, in 
collaboration with Central Sydney Area Health Service. It was established as a 
UTS Centre in February, 2002. The Centre aims to contribute to the development 
and application of health economics and health services research through 
research, teaching and policy support. CHERE’s research program encompasses 
both the theory and application of health economics. The main theoretical 
research theme pursues valuing benefits, including understanding what 
individuals value from health and health care, how such values should be 
measured, and exploring the social values attached to these benefits. The 
applied research  focuses on economic and the appraisal of new programs or new 
ways of delivering and/or funding services. CHERE’s teaching includes 
introducing clinicians, health services managers, public health professionals 
and others to health economic principles. Training programs aim to develop 
practical skills in health economics and health services research. Policy 
support is provided at all levels of the health care system by undertaking 
commissioned projects, through the provision of formal and informal advice as 
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A randomized controlled trial comparing the use of PET versus no PET provided the 
opportunity to investigate the value patients placed on any additional information 
provided by the PET scan. Interviews were undertaken with patients after their diagnosis 
had been made and, in the case of those who had surgery, once they had returned home 
following the operation. Content analysis was used to describe and analyse the text of the 
interviews. The aims of the research were to explore with people receiving PET their 
perceptions of its impact on aspects of well being, acquire a better understanding of how 
patients understand and deal with the outcomes (both benefits and dis-benefits) of PET,  
and assess the decision making processes regarding PET and subsequent treatment 
(surgical and non-surgical) from the patients’ perspectives with the aim of providing 
information which can be used by providers of care in improving the process of care. 
Interviews were conducted with a sub-sample of 59 trial participants between February 
2000 and July 2001, between six and eight weeks post-surgery. Thirty-three, (56%) had 
received a PET scan and 26 (44%) had not. The majority of patients consulted a surgeon 
in the expectation of having surgery to remove their cancer. Participants viewed PET 
(along with the other tests) as being most likely to provide information and reassurance to 
the surgeon, rather than having any impact on their (patients’) decisions. As far as these 
participants were concerned, there was only one important decision - whether to have 
surgery - and that decision was in the hands of the surgeon. All other decisions were 
subordinate to this major milestone and thus did not appear significant to patients. Thus, 
on its own, PET appeared to be of little additional value to this group of patients. 
Between 23%-45% of respondents reported some complications whilst in hospital or 
some difficulties at home but these were mostly of a relatively minor nature. Even though 
some patients reported that their health was worse than when they entered hospital, most 
participants reported that their health was improving at the time of the interview. Most 
participants had, at least briefly, discussed the issue of relapse with a doctor at a 
consultation subsequent to their surgery. The diagnosis of cancer is the key issue; all that 
happens to them subsequently seems to be determined by clinicians. It is important that 
clinicians explain the reasons for tests such as PET to patients and use diagnostic tests 
appropriately in the management of the disease. Understanding the experiences of 
patients provides useful information for clinicians in preparing patients for surgery for 
lung cancer and for cancer services in considering the level of ongoing support required 




PET has been proposed as a valuable tool for clinicians in the diagnosis and subsequent 
management of cancer, particularly those types that involve major surgery as a first line 
of treatment. Once an initial diagnosis is made, it is critical that the cancer be staged as 
accurately as possible to facilitate the most appropriate management of the disease. In 
particular, accurate staging is necessary to avoid unwarranted interventions (e.g. major 
surgery in the case of advanced cancer) and thus reduce unnecessary pain and suffering.  
 
Positron emission tomography (PET) is a relatively new imaging technology with 
potential to improve pre-operative staging.  Many malignant tumours show increased 
glucose utilisation when compared to normal tissues (1987). Whole body PET with 
18F-
fluorodeoxyglucose (FDG) can identify regions of increased glucose metabolism in non-
enlarged structures, allowing detection of tumour metastases earlier than with anatomic 
imaging methods. Non-small cell lung cancer (NSCLC) accounts for approximately 80% 
of all lung cancer.  At presentation, approximately 25% of patients have disease suitable 
for surgical resection (Nesbitt, Putnam, Walsh, Roth et al 1995). Following surgical 
resection, up to 40% of patients with clinical stage I disease and 60% of patients with 
clinical stage II disease ultimately relapse, implying that they had occult metastatic 
disease at the time of presentation. Such patients do not benefit from surgery, and the 
ability to identify them could save an unnecessary thoracotomy.  
 
Data suggest PET may improve the accuracy of pre-operative staging of NSCLC, but, in 
general, these results are from small, retrospective, uncontrolled series  
(Saunders, Dussek, O'Doherty & Maisey 1999; Weder, Schmid, Bruchhaus, Hillinger et 
al 1998; Wahl, Quint, Greenough, Meyer et al 1994). A recent prospective uncontrolled 
study reported sensitivity and specificity of PET for detection of mediastinal and distant 
metastatic disease of 95 per cent and 83 per cent, respectively (Pieterman, van Putten, 
Meuzelaar, Mooyaart et al 2000). PET is costly, and resource implications of its 
widespread use in staging NSCLC are significant.  There is increasing pressure for PET 
to be included in the standard diagnostic work-up prior to decisions about surgical 
management of NSCLC (Berlangieri &  Scott 2000; Robert &  Milne 1999). 
 
Whilst the results of PET scans may be valuable to clinicians, no information is available 
about patients’ perceptions of their usefulness or value. For example, a PET scan result 
indicating that the cancer has not spread beyond the lung may be reassuring to patients 
and be valued positively. On the other hand, if the PET scan indicates that the cancer has 
spread, patients may perceive a trade-off between the positive aspect of such a result (ie 
surgery may be avoided) and the negative one (ie more widespread disease probably 
means a poorer prognosis). The trial described below provided an opportunity to 
investigate these issues. 
 
A randomized controlled trial was undertaken comparing the use of PET versus no PET 
in 183 people with a clinical diagnosis of Stage I-II non-small cell lung cancer. The 
recommended treatment for these patients is surgery to remove the affected lung or part 
thereof. The overall research question was “to what extent does a “positive” PET scan 
result (ie a result which indicates that the cancer is at a more advanced stage than Stage 1) 
change the management of the disease?” Following exclusion of one ineligible patient, 92 
patients were assigned to no-PET and 91 to PET. Compared with conventional staging  
 
PET upstaged 22 patients, confirmed staging in 61 and staged two patients as benign. 
Stage IV disease was rarely detected (2 patients).PET led to further investigation or a 
change in clinical management in 13% of cases, and provided information that could 
potentially have affected management in a further 13% of cases. There was no significant 
difference between the trial arms in the number of thoracotomies avoided (p=0.2). It was 
concluded that for patients who are carefully and appropriately staged as having stage I-II 
disease, PET provides potential for more appropriate stage-specific therapy, but may not 
lead to a significant reduction in the number of thoracotomies avoided. Details of the trial 
and results have been reported elsewhere (Viney, Boyer, King, Kenny et al 2004). 
 
In addition to answering this question, the trial also provided the opportunity to 
investigate of a number of related issues such as the costs and quality of life associated 
with this group of patients and the value patients placed on any additional information 
provided by the PET scan. In this paper, the latter issue is addressed through qualitative 
analysis of interviews undertaken with patients after their diagnosis had been made and, 
in the case of those who had surgery, once they had returned home following the 
operation. 
 
Qualitative research methods in health care 
Qualitative research has become increasingly popular in the evaluation of health care and 
health services. This type of research answers questions that cannot be addressed using 
quantitative methods. The types of issues that are often investigated using qualitative 
research include the emotions, perceptions and actions of people with a particular disease 
or condition and the interactions between users and providers of health care services.  
 
There are numerous paradigms within the discipline of qualitative research; at one end of 
the spectrum are the use of techniques of data production and analysis as they relate to 
textual or non-numerical data whilst at the other is the explicit use of specific theories 
derived from, for example, grounded theory, sociology, ethnology or anthropology to 
investigate individual’s understanding and experiences of their lives and the social 
context in which events (such as exposure to health care) occur. The research reported 
here falls into the first category of qualitative research as it employs content analysis to 
describe and analyse text.  
 
The aims of this research were to: 
•  explore with people receiving PET their perceptions of its impact on aspects of 
well being. In particular, to investigate the potential impacts of information, 
reassurance and the morbidity associated with the surgery itself; 
•  acquire a better understanding of how patients understand and deal with the 
outcomes (both benefits and dis-benefits) of PET, in particular the trade-offs 
between earlier knowledge of metastatic disease and avoidance of (unnecessary) 
surgery; 
•  assess the decision making processes regarding PET and subsequent treatment 
(surgical and non-surgical) from the patients’ perspectives; and 
•  provide information which can be used by providers of care in improving the 






Interviews were conducted with a sub-sample of trial participants between February 2000 
and July 2001. Interviews occurred between six and eight weeks post-surgery, so that 
most patients would have largely recovered from the effects of the operation. 
Arrangements were made by phone to interview patients in their home and, when 
telephone contact was made, it was explained that, if possible, the interviewer would like 
to tape the conversation. All participants read an information sheet and consent form and 
all consented to have the interview audiotaped. Consecutive participants in the trial were 
approached about their willingness to be visited and interviewed. Most participants lived 
in or near Sydney and the interviewer traveled to the Central Coast and Wollongong as a 
significant proportion of participants lived in these areas. Two participants declined to 
participate and three were not approached because they did not speak and/or understand 
English well enough to be interviewed. Two researchers undertook alternate interviews 
with the first ten participants. The resulting interviews were transcribed and read by both 
researchers, each of whom produced a simple summary of the interview and highlighted 
issues raised by it. Based on these initial results, additional questions and/or probes were 
formulated. One researcher completed the remainder of the interviews. Data collection 
was completed when the interviews ceased to yield new information – i.e. when 
saturation was reached. 
 
The taped interviews were transcribed verbatim by a commercial secretarial firm. Written 
instructions were provided to the firm asking them not to transcribe the names of 
individuals but to use the first letter of names used by the interviewer and interviewee to 
preserve anonymity.  
 
Data analysis 
The transcribed interviews were analysed using a content analysis technique. Content 
analysis involves breaking text into relatively small units of content and submitting them 
to descriptive and/or statistical analysis (Lieblich, Tuval-Mashiach & Tamar-Zilber 
1998). This is generally accomplished by selecting sections of text or single words 
belonging to a defined category, describing the categories and counting the number of 
times each appears. Categories may be based on words, phrases or ideas (Kellehear 
1993). Aspects of text which may be quantified include: time or space measures (e.g. the 
space devoted to a topic in the media or the time devoted to it on television); appearances 
(e.g. how many times did a particular issue or person or type of person appear in the text); 
and intensity (the importance or prominence given to the topic).  
 
To be viewed as credible (reliable and valid), content analysis must be comprehensive, 
that is, all relevant sources of data should be examined. In addition, the categories must 
be clearly defined and specific, that is, be able to be used by a non-expert, and not be 
overlapping (Scott 1990). Content analysis is a widely used form of analysis and has 
some well-described advantages: using categories makes it clear what has been searched 
for and from where the information has come; others are easily able to check the data and 
method of classification; the connection between the data and subsequent interpretations 
is precise and explicit and; using categories in a systematic way avoids the tendency of 
researchers to analyse and interpret according to preconceived notions and/or intuition.  
  
 
                                                
Content analysis was judged to be an appropriate analytic tool because it is able to use the 
stages of diagnosis, treatment, recovery etc experienced by participants as categories. The 
categories used were those defined by the stage of management of NSCLC (ie diagnosis 
and treatment) and the three main issues discussed with respondents: their health (before 
and after treatment), relapse and life expectancy.  
 
Results 
A total of 59 individuals were interviewed following their diagnosis and treatment. Of 
these, 33 (56%) had received a PET scan and 26 (44%) had not. That is, 32% of trial 
participants also received a follow-up interview, 36% of those in the PET arm of the trial 
and 28% of those in the non-PET arm. One (control) patient’s status had changed 
between the initial treatment and the time of the interview – in this case the cancer had re-
occurred.   
 
Diagnosis 
Having a PET scan did not appear to influence individual’s experience of or perception of 
the time taken to make a diagnosis or the results of that diagnosis – all participants had 
multiple diagnostic tests (e.g. blood tests, X-Rays, CT scans, broncoscopy) so the 
addition of a PET scan did not loom large in the overall scheme of things. Of the 33 
people who had a PET scan, 28 remembered having the scan and 8 stated that they were 
explicitly told the scan was to “check for the spread of cancer”. There were 28 “positive” 
responses to a question about the results of the PET scan
1. These ranged from being told 
the results were good (1) to having no other cancer (12) and that the results did not 
change the planned treatment (15). Participants who received good news from the PET 
scan results gave only positive responses to the question – that is, they had no negative 
perceptions regarding the value of PET. Five respondents volunteered that having the 
PET scan gave them peace of mind or reassurance. 
 
The 8 “negative” responses included one respondent who stated that s/he didn’t know the 
results of the tests as her/his daughter was told the cancer had spread, 2 who stated that 
the planned treatment was changed as a result of the PET scan and 5 who reported that 
the PET scan revealed the cancer had spread. In addition to the “negative” responses 
reported above, participants whose results indicated that treatment needed to be changed 
or that the cancer had spread also indicated that they felt positively about the PET scan; 
for example, that, although the results were not as good as they had hoped, it was better 
to know than not. That is, they recognized the trade-off between information and bad 
news and generally preferred information because they believed that treatment outcomes 
would, overall, be better with full information.  
 
“if it wasn't for the PET scant they might have missed some…. I mean they were looking 
at taking the top lobe and then after the PET scan it was sorry we're going to have to go 
a bit more …and he got it all…he said to me we got it all, no chemo no radio”    (ID 108) 
 
Treatment 
Approximately 80% of the respondents in both PET and non-PET groups provided 
information about their experience of surgery and post-surgery hospitalization. Most 
 
1 This does not mean that there were responses from 28 individuals as respondents could provide more than 
one response in the course of answering the question or discussing the issue of the results of the PET scan.  
 
reported that they experienced little pain or that the pain was controllable. Fifteen people 
(45%) in the PET group and 14 (54%) in the control group reported that their surgery and 
hospitalisation went well and that they recovered well. However, 10 (30%) members of 
the PET group and 6 (23%) in the control group reported that they experienced some 
problems or complications following surgery, for example:   
 
“I had an adverse reaction to morphine….. 48 hours after the operation I 
woke up in the middle of the night with the most dreadful abdominal pains 
and I had to rush out to the bathroom very quickly and, to be perfectly 
honest I was so violently sick - vomiting and the most dreadful diarrhea, 
and for the next four nights I was getting up 6 and 7 times a night and I 
knew this was doing something to me”   (Female aged 77 years) 
 
“I had complications with the trachea or the oesophagus - it kinked and I 
had projectile vomiting…for a day and a half and then two days after it 
they put a tube down to try and straighten it…went back to nothing by 
mouth for three days”   (Male, aged 72 years)  
 
“Yes I had some complications.  I should've been home in 5 to 6 days but 
my bowels ceased to operate and I understand they didn’t know why that 
happened ……and I had to go back up to surgery because I had a hole and 
it was leaking……and then they realised I had polyps in my bowels so I 
had to go back up to surgery for that”   (Female, aged 61 years) 
 
Ten (30%) of those in the PET group  and 7 (27%) of those in the control group reported 
that their stay in hospital was shorter than they had expected but only one person 
volunteered that they perceived they had been discharged too early from hospital. 
 
Fifteen (45%) of the PET group reported experiencing some problems at home: of these 
10 experienced physical problems, 2 emotional problems and 3 reported that they took 
longer than expected to recover. Of the 10 who reported physical problems, only 4 said 
they needed assistance for personal or daily activities. In the control group, 9 (35%) 
reported problems once they were home (5 physical, 1 emotional and 3 took longer to 
recover than expected). The majority (85% PET; 96% control) reported that they were 
having regular or further check-ups with a medical practitioner and 48% of the PET 
group and 42% of the control group reported that they needed no further treatment. A 
number reported that they had received additional treatment such as radiotherapy (9 PET; 
10 control), chemotherapy (1 PET; 1 control) or other treatment (drug trial, herbologist, 
physiotherapy, as well as treatment for unrelated conditions – 3 PET; 3 control). 
 
Health  
Seventeen (52%) of the PET group and 11 (42%) of the control group commented on 
their general health status following surgery. Most perceived that it was much the same as 
previously, or returning to normal but 5 members of the PET group reported that their 
health was worse. Twelve (36%) in the PET group and 12 (46%) in the control group 
reported that problems with their breathing contributed to lower health status. Fourteen (8 
PET; 6 control) reported pain, tightness or discomfort in the chest, related to the surgery, 
13 (7 PET; 6 control) reported having less energy and 21 (14 PET; 7 control) reported 




Twenty four (73%) of the PET group and 19 (73%) of the control group reported 
discussing the probability and consequences of relapse (ie recurrence or spread of the 
cancer) with their doctor. Of these, 12 (36%) of the PET group and 9 (35%) of the control 
group reported that the doctor indicated a relapse was possible whilst very few said it was 
probable (1 PET; 3 control) or unlikely (2 PET; 1 control). More than half of those who 
reported discussing the likelihood of relapse with the doctor reported that they, rather 
than the doctor brought up the subject (15 PET; 11 control). Fourteen (42%) members of 
the PET group and 8 (31%) in the control group reported that they continued to think 
about relapse whilst smaller numbers (9 PET; 10 control) reported that they did not think 
about it.  
 
Life expectancy 
More than 70% in each group indicated that they expected or hoped to live the same 
length of life as they would have without the cancer. A number of participants stated that 
the surgical removal of the cancer meant that they now had the same chance of living a 
“normal” length as if they had not been diagnosed with the disease. But when the 
interviewer asked about specific expectations, a more complex set of issues emerged. 
Seventeen (52%) of the PET group and 16 (61%) of the control group indicated that their 
expectations had not changed, saying that they were getting on with life, had faith they 
were cured or accepted that things often do not go to plan so did not have any particular 
expectations, for example:  
 
“Well I do exactly the same things as I was doing a couple of years ago -  no 
difference”   (Male, aged 73 years) 
 
 
“We're still going to go away in our caravan next year”   (Female, aged 75 years) 
 
Eight  (24%) of the PET group and 5 (19%) of the control group indicated that their 
expectations had changed, explaining that their horizons had narrowed, they believed that 
they were getting older and needed to prepare their family for the worst and that they 
didn’t plan too far ahead.  The following quotations from four different participants 
illustrate this: 
 
“I'm not getting any younger and my body obviously must be slowing down 
and, I might be able to swing the shovel but I can't swing the pick.  See what 
I'm saying - you know I'm saying, -obviously you're not going to be going in 
the Olympics”   (Male, aged 81 years) 
 
 “Yes I do think differently…… I've come to accept that I may not live to a 
ripe old age but at least I'm not young. You know, if I was young I'd have a 
different attitude I suppose but I've had my life and let somebody else have a 
go now” ……My daughter won't let me talk about it because every time I 
say to her -  you know I might not be here, she says don't talk like that mum, 
she gets really upset about it and so does my husband.  I mean he's worse 
than she is”   (Female, aged 63 years) 
  
 
“ I got a boy and a girl, oh they're grown up married children and, I said to 
them you know what's going on here… of course you plant the seed in their 
brain, in their head”  (Male, aged 77 years) 
 
“Oh yes, I don't think very far ahead at all. I mean I don't plan something in 
the distant future,  like when they went to sell the tickets for the Olympics 
there was no way I was going to buy one because that's a year away.  We 
went on holidays in November and normally we'd have planned for that 
quite a bit longer and this time it's only about a month before we went we 
planned everything”   (Male, aged 51 years) 
 
An interesting finding was that 16 (48%) of the PET group reported having changed 
feelings about life – specifically, 12 said that they regarded each day they were alive as a 
bonus, whilst only 3 (12%) of the control group reported these feelings. 
 
Discussion 
The main aim of this research was to examine the perceptions and values of people with 
NSCLC regarding the use of PET as an additional diagnostic tool – in particular, its role 
in the provision of information, reassurance and the prevention of unnecessary surgery. In 
doing so, we expected to be able to assess how patients traded-off earlier knowledge of 
metastatic disease and the avoidance of painful surgery.  
 
However, the results of the trial of PET for Stage I-II, which aimed to assess its role in 
the management of NSCLC, showed that while PET had the potential to indicate more 
appropriate stage-specific therapy, it did not lead to a significant reduction in the number 
of thoracotomies avoided. The results of this qualitative research support these findings. 
The majority of patients consulted a surgeon in the expectation of having surgery to 
remove their cancer and most were convinced, prior to PET or any diagnostic test 
performed after the consultation, that they were having surgery. Those who had a PET 
scan regarded it as one amongst many diagnostic tests which they perceived as aiding or 
confirming the clinical skills of the surgeon. Thus, participants in the trial viewed PET 
(along with the other tests) as being most likely to provide information and reassurance to 
the surgeon, rather than having any impact on their (patients’) decisions. Whilst a number 
of individuals had their cancer upstaged as a result of PET, very few subsequently faced 
the trade-off between earlier diagnosis of metastatic disease and surgery. Thus, on its 
own, PET appeared to be of little additional value to this group of patients. Most 
recipients of PET understood it to be a more advanced version of a CAT scan and were 
grateful for the availability of such a sophisticated test. A number voiced the opinion that 
it should be more widely available. 
 
The main reason that PET seems not to have been particularly valuable to participants 
appears to be related to the notion, apparently shared by both surgeons and patients, that 
the clinician was both ethically obliged and accountable for making this particular type of 
decision. This in turn is related to patients’ perceptions of the clinical skills of the 
surgeons involved in the trial and their ability to inspire confidence in their patients. 
Because they understood the significance of their cancer being classified as stage I-II, 
(i.e. in terms of their capacity to have and benefit from surgery), patients relied on 
surgeons to provide them with information about the stage of the cancer and hence the 
chance of its being able to be treated by surgical removal. Overall, participants expressed  
 
great faith in the competence of the surgeon they consulted, in terms of both diagnostic 
and surgical skills. Thus, their attitude to the results of the PET scan is a reflection of 
their faith and belief in the capacity of the surgeon to correctly stage the cancer. Being 
offered surgery was perceived as an indication that the diagnosis of cancer, while 
shocking, was not as great a threat as it might be and patients were very happy to be 
operated on. 
 
Although there has been much discussion in the literature about the value of PET as a 
means of both diagnosing and staging lung cancer and its potential impact on clinical 
decision making (Weng, Tran, Rege, Safa et al 2000; Wren, Stijns & Srinivas 2002; 
Sachs &  Bilfinger 2005), there has been little investigation of the importance of the 
technology from patients’ perspectives. Papatheofanis (2000) obtained utilities for stage-
dependent outcomes for NSCLC and found that patients valued the information from 
non-invasive PET and invasive mediastinoscopy equally. This result may indicate that, 
although patients responded to the utilities questionnaire in a similar vein to participants 
in the current study, they did not believe they had the skills to differentiate between the 
two diagnostic technologies as the information gained from them was primarily for the 
benefit of clinicians and clinical decision making. 
 
Having reached the conclusion that the patients in our study perceived that the value of 
PET was primarily related to the provision of information for clinicians, the other aims of 
the research, (ie examining the decision making processes used by patients and the 
amount of information they required), seem somewhat redundant. As far as these 
participants were concerned, there was only one important decision - whether to have 
surgery - and that decision was in the hands of the surgeon. All other decisions were 
subordinate to this major milestone and thus did not appear significant to patients. A 
recent paper by Wirtz, Cribb and Barber (2006) highlights possible explanations for the 
lack of involvement or interest in decision making by some patients. Current models of 
doctor-patient decision making fail to address which decisions patients should be 
involved in and how they should be involved. Clearly, patients in this study did not feel 
they should be involved in the decision about whether surgery was appropriate and, 
thereafter, any involvement in the process was as a recipient of information rather than as 
equal partners in any reasoning-communication process. When the options for treatment 
are small and there is likely to be a strong preference on the part of the provider or patient 
(or both) for one, then shared decision making is not appropriate. Moreover, in the case 
of a risky procedure such as major chest surgery, ethical obligations on the part of the 
surgeon entail being accountable for the success of the procedure and therefore for the 
decision about whether to recommend it for individual patients.  
 
In general, participants in this trial indicated that they had either sufficient or too much 
information. This appears to be because they had numerous, sometimes repeated 
diagnostic tests. Once the diagnosis of cancer was made and the Stage confirmed and 
they had been told the exact site of the cancer and the type of surgery they would have 
(e.g. lobectomy, removal of entire lung), most patients felt they had enough information. 
However, useful information has been obtained about participants’ experiences of 
diagnosis, hospital care and surgery and their attitudes to issues regarding their health, 
including relapse and life expectancy. 
  
 
One possible side-effect of the generally positive attitudes to major surgery may have 
been the low reported rate of major problems during hospitalisation and at home 
following surgery. Although 23%-45% of respondents reported some complications 
whilst in hospital or some difficulties at home, these were mostly of a relatively minor 
nature. Even though some patients reported that their health was worse than when they 
entered hospital, most participants reported that their health was improving at the time of 
the interview. These findings reinforce those of the associated investigation of health-
related quality of life (HRQOL) of these patients (Kenny, King, Viney, Boyer et al 2007) 
Surgery substantially reduced HRQOL across all dimensions (i.e. physical, role, 
cognitive and social functioning) except emotional. HRQOL improved considerably in 
the first month following surgery and continued to improve for patients without 
recurrence. However, around half continued to experience symptoms and functional 
limitations two years after surgery (Kenny, King, Viney, Boyer et al 2007).  
 
Most participants had, however briefly, discussed the issue of relapse with a doctor at a 
consultation subsequent to their surgery. Understandably, participants were less 
forthcoming about this issue and that of life expectancy than they were about their 
experiences before, during and after surgery. For some, this was due to the fact that they 
had little real information to go by- although a number spoke of knowing the probability 
of relapse for the average person in their position, most also understood that there was no 
way of knowing if they were, in fact, “typical”. For others, not discussing these issues 
meant that they felt they were not worrying their family or were better able to cope by 
“getting on with life”.  
 
The fact that they were able to have surgery may also have contributed to respondents’ 
positive responses to questions about how long they expected to live. A belief that a 
positive attitude would contribute to their chances of surviving into old age may also 
have influenced some responses. A number of participants indicated that they felt a need 
to remain positive for the sake of their family.   
 
Limitations of the study 
Whilst the results of qualitative research produce in-depth information about feelings, 
perceptions and experiences of health care, the extent to which they are generalisable to 
other groups or the wider population is limited. Hence the results reported here apply to 
this group of (mostly) men, with Stage I or II lung cancer treated by surgery either in a 
large tertiary hospital or a private hospital in Australia. Only 59 of a potential 173 
participants were interviewed. However, there is no reason to expect that information 
supplied by other participants would have added to our knowledge as the sub-sample 
included in the qualitative study had a similar socio-demographic and clinical profile to 
study participants as a whole. 
 
Conclusion 
For those patients who participated in this study, the diagnosis of cancer is the key issue; 
all that happens to them following this seems to be determined by clinicians. Therefore, it 
is important that clinicians explain the reasons for tests such as PET to patients and use 
diagnostic tests appropriately in the management of the disease. The experiences of 
patients provides useful information for clinicians in preparing patients for surgery for 
lung cancer and for cancer services in considering the level of ongoing support required 
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